Immusoft is advancing engineered B cell therapies across rare disease and high-prevalence indications. By leveraging our Immune System Programming (ISP™) platform, we believe that we can develop therapeutics with the potential to deliver meaningful functional improvements for patients.
We have a broad pipeline, with our lead program in MPS I (Mucopolysaccharidosis type I), and preclinical programs in rare diseases and other indications with significant unmet need.
-
ISP-001
MPS I
Discovery IND-Enabling Phase 1/2a Pivotal -
ISP-002
MPS II
Discovery IND-Enabling Phase 1/2a Pivotal -
Gaucher
Discovery IND-Enabling Phase 1/2a Pivotal -
Parkinson’s
Partnering TargetDiscovery IND-Enabling Phase 1/2a Pivotal -
Obesity / Diabetes
Partnering TargetDiscovery IND-Enabling Phase 1/2a Pivotal -
Oncology
Partnering TargetDiscovery IND-Enabling Phase 1/2a Pivotal -
Autoimmune
Partnering TargetDiscovery IND-Enabling Phase 1/2a Pivotal